409 related articles for article (PubMed ID: 11448564)
1. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O
Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
Blondeau JM; Hansen G; Metzler KL; Borsos S; Irvine LB; Blanco L
Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Evangelista AT; Critchley IA; Sahm DF
Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Yong DE; Cheong HJ; Kim YS; Park YJ; Kim WJ; Woo JH; Lee KW; Kang MW; Choo YS
J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
[TBL] [Abstract][Full Text] [Related]
12. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
[TBL] [Abstract][Full Text] [Related]
16. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
Bongaerts GP; Hoogkamp-Korstanje JA
Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
[TBL] [Abstract][Full Text] [Related]
18. Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA.
Karlowsky JA; Jones ME; Mayfield DC; Thornsberry C; Sahm DF
Int J Antimicrob Agents; 2002 May; 19(5):413-26. PubMed ID: 12007850
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
20. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
